Kyverna Reported Positive Miv-Cel Trial Results
The company recorded long-term clinical benefits in patients with stiff-person syndrome ahead of a 2026 license filing.
Updated on Sept. 24, 2026 in Biotech
Live Poll
Do you believe the clinical benefits of new cell therapies justify the risks for patients?
Kyverna Therapeutics released 12-month clinical trial results for its miv-cel cell therapy, showing significant physical improvements in patients with stiff-person syndrome. These findings represent completed research-stage clinical outcomes rather than a commercially available treatment.
Why it matters
The study validates the potential for targeted cell therapies to treat autoimmune disorders, moving closer to a regulatory filing. The results suggest a potential reduction in long-term reliance on chronic immunosuppressive drugs for this patient population.
In the KYSA-8 trial, 95% of patients who achieved initial clinical benefits maintained them at 12 months, with 92% of participants remaining free from chronic immunotherapies. Additionally, 67% of those previously requiring assistance continued to walk without aids.
The players
Kyverna Therapeutics
A clinical-stage biopharmaceutical company developing cell therapies aimed at treating autoimmune diseases.
The details
Miv-cel is a cell therapy, a treatment that uses modified human cells to treat or cure disease, administered to participants in the KYSA-6 and KYSA-8 trials. The KYSA-8 study measured outcomes by comparing timed 25-Foot Walk performance, a physical test used to assess mobility, against baseline measurements taken before treatment. By removing the need for daily immunosuppressive medications, the therapy aims to reset the immune system responses associated with stiff-person syndrome, a rare neurological condition.
Timeline
June 2026: Data lock occurred for the KYSA-6 trial follow-up.
July 2026: Data lock occurred for the KYSA-8 trial follow-up.
Q4 2026: The company plans to submit its Biologics License Application.
Mid-2027: Enrollment is expected to complete for the KYSA-6 Phase 3 study.
The Tech Race
This development marks a significant milestone in the KYSA-6 clinical trial program as Kyverna advances its cell therapy pipeline. The results position the company to maintain its competitive trajectory toward a planned regulatory filing in late 2026.
This therapy is currently restricted to clinical trial participants and is not yet available for general prescription. Patients and providers should track the company's progress toward the late 2026 regulatory submission to gauge the eventual timeline for potential clinical access.
The takeaway
The data confirms that miv-cel therapy can provide sustained improvements in mobility for patients with stiff-person syndrome. Stakeholders should monitor the Biologics License Application submission slated for the fourth quarter of 2026 as the primary indicator for potential regulatory progress.
What happens next
Kyverna Therapeutics is scheduled to submit its Biologics License Application in the fourth quarter of 2026, followed by the planned completion of enrollment for the KYSA-6 Phase 3 study in mid-2027.
Further reading
For broader trends in emerging therapies, see the latest developments in Biotech.
Live Poll
Do you believe the clinical benefits of new cell therapies justify the risks for patients?
